$136.12
0.90% yesterday
NYSE, Jun 13, 10:10 pm CET
ISIN
US23918K1088
Symbol
DVA

DaVita HealthCare Partners Stock price

$136.12
-7.86 5.46% 1M
-16.61 10.88% 6M
-13.43 8.98% YTD
-6.04 4.25% 1Y
+57.59 73.34% 5Y
+54.84 67.47% 10Y
+113.10 491.18% 20Y
NYSE, Closing price Fri, Jun 13 2025
-1.23 0.90%
ISIN
US23918K1088
Symbol
DVA
Sector

Key metrics

Market capitalization $10.28b
Enterprise Value $19.50b
P/E (TTM) P/E ratio 12.88
EV/FCF (TTM) EV/FCF 11.09
EV/Sales (TTM) EV/Sales 1.50
P/S ratio (TTM) P/S ratio 0.79
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 5.11%
Revenue (TTM) Revenue $12.97b
EBIT (operating result TTM) EBIT $1.95b
Free Cash Flow (TTM) Free Cash Flow $1.76b
Cash position $511.94m
EPS (TTM) EPS $10.57
P/E forward 12.65
P/S forward 0.76
EV/Sales forward 1.45
Short interest 14.88%
Show more

Is DaVita HealthCare Partners a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

DaVita HealthCare Partners Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a DaVita HealthCare Partners forecast:

2x Buy
17%
9x Hold
75%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a DaVita HealthCare Partners forecast:

Buy
17%
Hold
75%
Sell
8%

Financial data from DaVita HealthCare Partners

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
12,969 12,969
5% 5%
100%
- Direct Costs 8,759 8,759
5% 5%
68%
4,209 4,209
5% 5%
32%
- Selling and Administrative Expenses 1,550 1,550
3% 3%
12%
- Research and Development Expense - -
-
-
2,659 2,659
7% 7%
21%
- Depreciation and Amortization 713 713
5% 5%
5%
EBIT (Operating Income) EBIT 1,946 1,946
12% 12%
15%
Net Profit 860 860
5% 5%
7%

In millions USD.

Don't miss a Thing! We will send you all news about DaVita HealthCare Partners directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DaVita HealthCare Partners Stock News

Positive
Market Watch
12 days ago
When selecting investments, it is easy to get hung up on a particular metric, such as a dividend yield or a price ratio, but investors need to look deeper or they might miss opportunities.
Neutral
PRNewsWire
15 days ago
DENVER , May 30, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita.
Positive
Seeking Alpha
18 days ago
International expansion continues with new clinics in Brazil, Ecuador, Chile, and Colombia, supporting long-term growth beyond the US market. DaVita's stock offers a 10% FCF yield, and the share count is decreasing at a fast pace. On top of share buybacks, the company will grow revenues above inflation due to its defensive business model and 35% market share.
More DaVita HealthCare Partners News

Company Profile

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Head office United States
CEO Javier Rodriguez
Employees 76,000
Founded 1994
Website www.davita.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today